Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Enterococcal Infections: A Comparative Analysis between the Pandemic and the Pre-pandemic Period

Author(s): Neha Sharad, Smriti Srivastava, Vandana Vijayeta Kiro, Sharin Varma, Sharad Srivastav, Aparna Ningombam, Rajesh Malhotra and Purva Mathur*

Volume 5, Issue 1, 2024

Published on: 06 November, 2023

Article ID: e061123223224 Pages: 7

DOI: 10.2174/0126667975266889231102063923

Price: $65

Abstract

Introduction: During the COVID-19 pandemic, higher Enterococcus bloodstream infections (BSI) rates have been reported. To establish whether these infections actually increased, we compared the incidence of Enterococcal infections before (September 2019 to February 2020) and during the pandemic (April 2020 to March 2022).

Materials and Methods: This retrospective observational study was conducted at a tertiary care center converted into a COVID-19 facility. All clinical samples received in our laboratory during the study period were included.

Results: In the six months preceding the pandemic, 2,243 samples were positive for bacterial growth; of the isolated organisms, 100 were Enterococcus species. During the pandemic, 39 out of 996 positive samples were Enterococcus. E. faecium was the most common isolate, 79/99 and 37/39. BSI was the most common overall infection (554/996; 55.6%) compared to the period before it (287/2243; 12.79%). Enterococcus species accounted for 30 out of 554 (5.41%) BSI in COVID-19 patients and 21/287 in the period before it (7.31%). Ten out of 39 (25.64%) isolates were vancomycin-resistant compared to the pre-COVID-19 period (9/21; 42.8%). There was an increase in antimicrobial resistance in the pandemic, except for linezolid and high-level aminoglycoside.

Conclusion: Although we noted a higher percentage of BSIs, Enterococci were isolated from a lesser rate of COVID-19 patients from our center compared to pre-pandemic times. The plausible reasons for this could be the protective gut microbiota in the Indian population, and no increase in Enterococcus species in the environment of patients.

Graphical Abstract

[1]
Thiercelin ME. On a saprophytic intestinal diplococcus likely to become pathogenic. C R Seances Soc Biol 1899; 50: 269-71.
[2]
Mundt JO. Enterococci. In: Sneath PHA, Mair NS, Sharpe ME, Holt JG, Eds. Bergey’s Manual of systematic bacteriology. Baltimore, MD: Williams & Wilkins 1986; Vol. 2: pp. 1065-5.
[3]
Polemis M, Mandilara G, Pappa O, et al. COVID-19 and antimicrobial resistance: Data from the Greek electronic system for the surveillance of antimicrobial resistance—WHONET-Greece (January 2018–March 2021). Life 2021; 11(10): 996.
[http://dx.doi.org/10.3390/life11100996] [PMID: 34685368]
[4]
DeVoe C, Segal MR, Wang L, et al. Increased rates of secondary bacterial infections, including Enterococcus bacteremia, in patients hospitalized with coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol 2021; 1-8.
[http://dx.doi.org/10.1017/ice.2021.391] [PMID: 34486503]
[5]
Giannitsioti E, Louka C, Mamali V, et al. Bloodstream infections in a cOVID-19 Non-ICU department: Microbial epidemiology, resistance profiles and comparative analysis of risk factors and patients’ outcome. Microorganisms 2022; 10(7): 1314.
[http://dx.doi.org/10.3390/microorganisms10071314] [PMID: 35889033]
[6]
Bonazzetti C, Morena V, Giacomelli A, et al. Unexpectedly high frequency of enterococcal bloodstream infections in Coronavirus Disease 2019 patients admitted to an Italian ICU: An observational study. Crit Care Med 2021; 49(1): e31-40.
[http://dx.doi.org/10.1097/CCM.0000000000004748] [PMID: 33122577]
[7]
Vijay S, Bansal N, Rao BK, et al. Secondary Infections in Hospitalized COVID-19 Patients: Indian Experience. Infect Drug Resist 2021; 14: 1893-903.
[http://dx.doi.org/10.2147/IDR.S299774] [PMID: 34079300]
[8]
Bazaid AS, Barnawi H, Qanash H, et al. Bacterial coinfection and antibiotic resistance profiles among hospitalised COVID-19 patients. Microorganisms 2022; 10(3): 495.
[http://dx.doi.org/10.3390/microorganisms10030495] [PMID: 35336071]
[9]
Santoso P, Sung M, Hartantri Y, et al. MDR pathogens organisms as risk factor of mortality in secondary pulmonary bacterial infections among COVID-19 patients: Observational studies in two referral hospitals in West Java, Indonesia. Int J Gen Med 2022; 15: 4741-51.
[http://dx.doi.org/10.2147/IJGM.S359959] [PMID: 35571285]
[10]
Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: A retrospective analysis. Antimicrob Resist Infect Control 2020; 9(1): 153.
[http://dx.doi.org/10.1186/s13756-020-00819-1] [PMID: 32962731]
[11]
Pasquini Z, Barocci I, Brescini L, et al. Bloodstream infections in the COVID-19 era: Results from an Italian multi-centre study. Int J Infect Dis 2021; 111: 31-6.
[http://dx.doi.org/10.1016/j.ijid.2021.07.065] [PMID: 34416402]
[12]
Budhiraja S, Tarai B, Jain D, et al. Secondary infections modify the overall course of hospitalized patients with COVID-19: A retrospective study from a network of hospitals across North India. IJID Regions 2022; 3: 44-53.
[http://dx.doi.org/10.1016/j.ijregi.2022.02.008] [PMID: 35720143]
[13]
Cataldo MA, Tetaj N, Selleri M, et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect”. J Glob Antimicrob Resist 2020; 23: 290-1.
[http://dx.doi.org/10.1016/j.jgar.2020.10.004] [PMID: 33130024]
[14]
Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest 2020; 50(10): e13319.
[http://dx.doi.org/10.1111/eci.13319] [PMID: 32535894]
[15]
Bhargava A, Riederer K, Sharma M, Fukushima EA, Johnson L, Saravolatz L. High rate of Multidrug-Resistant Organisms (MDROs) among COVID-19 patients presenting with bacteremia upon hospital admission. Am J Infect Control 2021; 49(11): 1441-2.
[http://dx.doi.org/10.1016/j.ajic.2021.08.010] [PMID: 34416313]
[16]
Protonotariou E, Mantzana P, Meletis G, et al. Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic wave. FEMS Microbes 2022; 2: xtab021..
[http://dx.doi.org/10.1093/femsmc/xtab021] [PMID: 35311247]
[17]
Khurana S, Singh P, Sharad N, et al. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol 2021; 39(2): 147-53.
[http://dx.doi.org/10.1016/j.ijmmb.2020.10.014] [PMID: 33966856]
[18]
Giacobbe DR, Labate L, Tutino S, et al. Enterococcal bloodstream infections in critically ill patients with COVID-19: A case series. Ann Med 2021; 53(1): 1779-86.
[http://dx.doi.org/10.1080/07853890.2021.1988695] [PMID: 34637370]
[19]
Gowardman JR, Robertson IK, Parkes S, Rickard CM. Influence of insertion site on central venous catheter colonization and bloodstream infection rates. Intensive Care Med 2008; 34(6): 1038-45.
[http://dx.doi.org/10.1007/s00134-008-1046-3] [PMID: 18317732]
[20]
Carrer S, Bocchi A, Bortolotti M, et al. Effect of different sterile barrier precautions and central venous catheter dressing on the skin colonization around the insertion site. Minerva Anestesiol 2005; 71(5): 197-206.
[PMID: 15834348]
[21]
Moro ML, Viganò EF, Lepri AC. Risk factors for central venous catheter-related infections in surgical and intensive care units. Infect Control Hosp Epidemiol 1994; 15(4): 253-64.
[http://dx.doi.org/10.2307/30145577] [PMID: 8207192]
[22]
Luft D, Schmoor C, Wilson C, et al. Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol 2010; 89(12): 1265-75.
[http://dx.doi.org/10.1007/s00277-010-1005-2] [PMID: 20532506]
[23]
Cohen B, Choi YJ, Hyman S, Furuya EY, Neidell M, Larson E. Gender differences in risk of bloodstream and surgical site infections. J Gen Intern Med 2013; 28(10): 1318-25.
[http://dx.doi.org/10.1007/s11606-013-2421-5] [PMID: 23605308]
[24]
Pawelec G. Immunity and ageing in man. Exp Gerontol 2006; 41(12): 1239-42.
[http://dx.doi.org/10.1016/j.exger.2006.09.005] [PMID: 17118601]
[25]
Mariat D, Firmesse O, Levenez F, et al. The firmicutes/bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009; 9(1): 123.
[http://dx.doi.org/10.1186/1471-2180-9-123] [PMID: 19508720]
[26]
Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5(5): e10667.
[http://dx.doi.org/10.1371/journal.pone.0010667] [PMID: 20498852]
[27]
Soraci L, Cherubini A, Paoletti L, et al. Safety and tolerability of antimicrobial agents in the older patient. Drugs Aging 2023; 40(6): 499-526.
[http://dx.doi.org/10.1007/s40266-023-01019-3] [PMID: 36976501]
[28]
Corsonello A, Abbatecola AM, Fusco S, et al. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect 2015; 21(1): 20-6.
[http://dx.doi.org/10.1016/j.cmi.2014.09.011] [PMID: 25636922]
[29]
Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med 2012; 28(2): 273-86.
[http://dx.doi.org/10.1016/j.cger.2012.01.007] [PMID: 22500543]
[30]
Page AT, Falster MO, Litchfield M, Pearson SA, Etherton-Beer C. Polypharmacy among older Australians, 2006–2017: A population based study. Med J Aust 2019; 211(2): 71-5.
[http://dx.doi.org/10.5694/mja2.50244] [PMID: 31219179]
[31]
Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr 2018; 78: 213-20.
[http://dx.doi.org/10.1016/j.archger.2018.06.018] [PMID: 30015057]
[32]
Zhang J, Lan P, Yi J, et al. Secondary bloodstream infection in critically ill patients with COVID-19. J Int Med Res 2021; 49(12)
[http://dx.doi.org/10.1177/03000605211062783] [PMID: 34898307]
[33]
Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: A narrative review. Intensive Care Med 2020; 46(5): 888-906.
[http://dx.doi.org/10.1007/s00134-020-05980-0] [PMID: 32157357]
[34]
Grasselli G, Scaravilli V, Di Bella S, et al. Nosocomial infections during extracorporeal membrane oxygenation: Incidence, etiology, and impact on Patients’ outcome. Crit Care Med 2017; 45(10): 1726-33.
[http://dx.doi.org/10.1097/CCM.0000000000002652] [PMID: 28777198]
[35]
Timsit JF, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med 2020; 46(2): 266-84.
[http://dx.doi.org/10.1007/s00134-020-05950-6] [PMID: 32047941]
[36]
Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: Incidence and predictive factors. Clin Microbiol Infect 2021; 27(3): 451-7.
[http://dx.doi.org/10.1016/j.cmi.2020.10.021] [PMID: 33223114]
[37]
López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, et al. Increment antimicrobial resistance during the COVID-19 pandemic: Results from the invifar network. Microb Drug Resist 2022; 28(3): 338-45.
[http://dx.doi.org/10.1089/mdr.2021.0231] [PMID: 34870473]
[38]
Polly M, de Almeida BL, Lennon RP, Cortês MF, Costa SF, Guimarães T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. Am J Infect Control 2022; 50(1): 32-8.
[http://dx.doi.org/10.1016/j.ajic.2021.09.018] [PMID: 34562526]
[39]
Gaibani P, D’Amico F, Bartoletti M, et al. The gut microbiota of critically ill patients with COVID-19. Front Cell Infect Microbiol 2021; 11: 670424.
[http://dx.doi.org/10.3389/fcimb.2021.670424] [PMID: 34268136]
[40]
Zhou Y, Shi X, Fu W, et al. Gut microbiota dysbiosis correlates with abnormal immune response in moderate COVID-19 patients with fever. J Inflamm Res 2021; 14: 2619-31.
[http://dx.doi.org/10.2147/JIR.S311518] [PMID: 34168484]
[41]
Rishi P, Thakur K, Vij S, et al. Diet, gut microbiota and COVID-19. Indian J Microbiol 2020; 60(4): 420-9.
[http://dx.doi.org/10.1007/s12088-020-00908-0] [PMID: 33012868]
[42]
Kampmeier S, Tönnies H, Correa-Martinez CL, Mellmann A, Schwierzeck V. A nosocomial cluster of vancomycin resistant enterococci among COVID-19 patients in an intensive care unit. Antimicrob Resist Infect Control 2020; 9(1): 154.
[http://dx.doi.org/10.1186/s13756-020-00820-8] [PMID: 32962759]
[43]
Shomuyiwa DO, Lucero-Prisno DE III, Manirambona E, et al. Curbing antimicrobial resistance in post-COVID Africa: Challenges, actions and recommendations. Health Sci Rep 2022; 5(5): e771.
[http://dx.doi.org/10.1002/hsr2.771] [PMID: 35949681]
[44]
Elmahi OKO, Uakkas S, Olalekan BY, et al. Antimicrobial resistance and one health in the post COVID-19 era: What should health students learn? Antimicrob Resist Infect Control 2022; 11(1): 58.
[http://dx.doi.org/10.1186/s13756-022-01099-7] [PMID: 35410463]
[45]
Pierce J, Stevens MP. COVID-19 and antimicrobial stewardship: Lessons learned, best practices, and future implications. Int J Infect Dis 2021; 113: 103-8.
[http://dx.doi.org/10.1016/j.ijid.2021.10.001] [PMID: 34624517]
[46]
Ghosh S, Bornman C, Zafer MM. Antimicrobial resistance threats in the emerging COVID-19 pandemic: Where do we stand? J Infect Public Health 2021; 14(5): 555-60.
[http://dx.doi.org/10.1016/j.jiph.2021.02.011] [PMID: 33848884]
[47]
Rodríguez-Baño J, Rossolini GM, Schultsz C, et al. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. J Glob Antimicrob Resist 2021; 25: 5-7.
[http://dx.doi.org/10.1016/j.jgar.2021.02.013] [PMID: 33662647]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy